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Background: The most common of the neuropathies associated with diabetes mellitus, diabetic 
sensorimotor polyneuropathy (DSPN) is a syndrome of diffuse, length-dependent, symmetric 
nerve dysfunction. The condition is linked with substantial morbidity, frequent healthcare 
utilization, and compromised quality of life due to related discomfort. Correspondingly, anti-
depressants, anticonvulsants, and opioids are regularly prescribed with the goal of pain control. 
However, the agents rarely provide complete pain relief and fail to address progression of the 
disorder. Whereas strict blood glucose control can slow the onset and worsening of DSPN, 
near-normoglycemia is not easily attainable. Evidence implicating oxidative processes in the 
pathogenesis of DSPN offers one potentially important therapeutic avenue. Due to its properties 
as a potent antioxidant, alpha lipoic acid (ALA) could mitigate the development of DSPN and 
attenuate resultant symptoms and signs. Approved for treatment of DSPN in Germany, the agent 
is not more widely used due to uncertainty about its efficacy and reported adverse effects. Here 
we review the effectiveness and tolerability of ALA in the treatment of symptomatic DSPN.
Methods: The MEDLINE, EMBASE, and Cochrane Library databases were searched for 
English-language literature on the topic. Randomized, blinded studies comparing parenteral 
and oral ALA with placebo in the treatment of peripheral neuropathy in diabetic adults were 
selected. Analysis included studies with a level of evidence of at least 2b.
Results: The current appraisal summarizes data from 1160 participants in the ALADIN, 
SYDNEY, ORPIL, SYDNEY 2, and ALADIN III trials. In four of the studies, ALA provided 
significant improvement in manifestations of DSPN.
Conclusion: Treatment with ALA 600 mg iv daily for 3 weeks represents a well-tolerated and 
effective therapy for DSPN. An oral dose of 600 mg daily administered for up to 5 weeks could 
offer benefits in symptoms and signs of DSPN without significant side effects.
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Introduction
Diabetes mellitus (DM) is estimated to affect 439 million adults throughout the world 
by 2030.1 Complications of DM include a variety of neuropathies, which can be 
classified as focal or diffuse.2 Cranial mononeuropathies, diabetic amyotrophy, and 
focal appendicular neuropathies fall into the ‘focal’ category. ‘Diffuse’ neuropathies 
include chronic inflammatory demyelinating polyneuropathy and diabetic sensorimotor 
polyneuropathy (DSPN), the latter being a condition characterized by generalized, 
length-dependent, symmetric nerve dysfunction.2
Of the neuropathies associated with DM, DSPN is the most common.2,3 The 
prevalence increases from 10% within the first year of a DM diagnosis to 50% after Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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25 years.4 Whereas the majority of cases are asymptomatic, 
symptomatic DSPN represents an important clinical   challenge 
in type 1 and type 2 DM populations.3,5 Beyond substantial 
morbidity and mortality, painful DSPN translates into emo-
tional distress, sleep disturbance, decreased productivity, and 
increased demands on healthcare resources.6–11
Given a reduced quality of life, it is not surprising that 
patients seek treatment for DSPN.7 Patients most commonly 
report hot, burning, electric, sharp, achy, and tingling 
sensations in a stocking-glove distribution.8 Many of these 
symptoms are attributable to small-fiber neuropathy, which 
often precedes large fiber dysfunction.2 Alternatively, patients 
may present with negative symptoms, such as numbness and 
gait unsteadiness, suggestive of large fiber damage.2
In the absence of alternative etiologies, length-dependent 
deficits in pinprick, temperature, light touch, proprioception, 
and vibration sense are objective markers of DSPN.2 
Abnormalities in strength and reflexes can also occur in 
advanced stages of disease.2,3 The concomitants of nerve 
fiber injury can be detected on nerve conduction studies and 
electromyography. Reductions in distal sensory response 
amplitudes and conduction velocities are evident prior to the 
development of motor abnormalities, thereby paralleling the 
clinical course of DSPN.2
Pathogenesis of DSPN
Chronic hyperglycemia is believed to play a key role in 
the pathogenesis of DSPN via oxidative stress generated 
in heterogeneous and overlapping pathways.12–14 Enhanced 
flux through the polyol pathway, glucose auto-oxidation, 
and accumulation of advanced glycation end-products are 
thought to cause oxidative stress; in turn oxidative stress 
downregulates Na-K-ATPase activity and results in nerve 
ischemia.12,14 Endoneurial hypoxia and microvascular damage 
may also occur from the downstream inactivation of nitrous 
oxide and, thereby, increased vascular tension coupled with 
decreased blood flow.12 Oxidative stress resulting from hyper-
glycemia is also reported to cause programmed cell death.12,14 
Increased sorbitol, decreased myo-inositol, protein kinase 
C activation, changes in cellular processing, and immune 
complex deposition may contribute to the development of 
DSPN.2,12,14
Treatment approaches: symptomatic  
and pathogenic
As adjuncts to antidiabetic agents targeting tight glycemic 
control, many treatments are prescribed with the goal 
of DSPN symptom relief. Evidence-based guidelines 
recommend the graded use of tricyclic antidepressants, 
serotonin–norepinephrine reuptake inhibitors, antiepileptic 
drugs, opioids, and mexiletine.15,16 Topical agents such as 
capsaicin and lidocaine are also suggested.15 The effectiveness 
of the existing approach is suboptimal; research shows that 
mono- and combination therapies almost never provide 
complete pain pelief.15
Until recently, glycemic control was the only treatment 
aimed at etiologic factors in DSPN. Indeed, strict glycemic 
control over 4–5 years can reduce, postpone, and possibly 
prevent the development of neurological deficits, nerve con-
duction abnormalities, and autonomic dysfunction.17,18 While 
an effective cornerstone of therapy, near-normoglycemia is 
not always possible to achieve or maintain.19,20 Given the role 
of oxidative processes in DSPN, antioxidants could offer 
additional therapeutic benefit. Among the emerging therapies, 
one of the most promising is alpha lipoic acid (ALA).
Alpha lipoic acid (Thioctic acid)
The only fat and water-soluble antioxidant,12 R-lipoic acid 
(1,2-dithiolane-3-pentanoic acid) was incidentally discovered 
by Snell et al in 1937 as a potato extract required for bacterial 
growth;21 the agent was later characterized by Reed and 
colleagues in 1951 (Figure 1).12,14,23,24 Ultimately revealed to 
function as a cofactor for mitochondrial enzymes, ALA is 
created endogenously by plants and animals.14 After uptake into 
cells and tissues, it is reduced to dihydrolipoic acid (DHLA).14 
Both ALA and DHLA are potent antioxidants, with the latter 
regenerating other factors such as vitamins C and E in addition 
to raising glutathione intracellularly.14,25 Further, both ALA and 
DHLA function as free radical scavengers.14,22
ALA is proposed to mitigate the development of DSPN 
by addressing reactive oxygen and nitrogen species that are 
overproduced in the setting of DM.14 In neuroblastoma cell 
cultures, the agent has been associated with the sprouting of 
neurites.26 In addition to a regenerative capacity, ALA offers 
protection against nerve ischemia in rats.12 Experimental 
models have also shown that the administration of ALA can 
significantly reduce the expression of glial and neuronal 
markers, decrease lipid peroxidation, and help correct deficits 
in nerve blood flow, oxidative stress, and distal sensory and 
motor nerve conduction.13,27,28
O
OH
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Although synthesized de novo, ALA can also be absorbed 
from the diet.25,29,30 Dietary supplements ranging in doses 
from 200–600 mg are likely to provide up to 1000 times the 
amount of ALA available from a regular diet.30 Preclinical 
and clinical data indicate ALA is bioavailable and safe in 
moderate doses.29 Gastrointestinal absorption is variable, 
and use with food decreases uptake.29,30 Accordingly, it is 
recommended that the agent be consumed 30 to 60 minutes 
before, or at least 120 minutes after, a meal.14,30 The 
antioxidant is very rapidly absorbed and cleared; maximum 
blood levels are achieved after 30 to 60 minutes, and the 
half-life of parenteral ALA is 30 minutes.30,31 It is thought 
to be extensively metabolized in the liver.14 Nevertheless, it 
is considered safe in hepatic and renal disease.22
Intravenous and oral forms of ALA are approved for the 
treatment of DSPN in Germany, where it is also covered 
by insurance.30,32 While not officially sanctioned in many 
  countries, oral formulations are readily available over the 
counter and online. The agent is relatively   inexpensive; 
in New Zealand currency, each 600 mg tablet costs about 
53 cents.33 Despite its qualities as a safe, available, inexpensive 
antioxidant, ALA is not widely used in part due to incomplete 
knowledge of its efficacy and adverse effects. The goal of this 
review is to assess the safety and effectiveness of treatment 
with parenteral and oral alpha lipoic acid on the symptoms, 
sensory deficits, and abnormal electrophysiological parameters 
of adults with symptomatic DSPN.
Methods
The MEDLINE, EMBASE, and Cochrane Library databases 
were searched for English-language literature on April 6 and 
April 11, 2011 using the terms ‘lipoic acid’, ‘alpha lipoic 
acid’, ‘thioctic acid’, ‘trometamol salt of thioctic acid’, 
‘diabetes’, ‘diabetic neuropathy’, and ‘painful peripheral 
neuropathy’. Randomized studies comparing the use of 
parenteral or oral ALA with placebo in the treatment of 
painful peripheral neuropathy in adults with type 1 and type 2 
DM were selected. Meta-analyses and systematic reviews 
were also considered. Information on adverse events was 
culled from the trials. The reference lists of articles were also 
reviewed. Studies evaluating the effect of ALA on autonomic 
neuropathy and diabetic mononeuropathy were excluded. 
Studies for which primary data could not be obtained were 
excluded. As the one meta-analysis reviewed did not adhere 
to the standards of the Cochrane Collaboration, it was not 
included in the primary review.32
 There was no disagreement among authors regarding the 
studies selected for inclusion.
Results
Five randomized double-blind placebo-controlled trials, the 
ALADIN, SYDNEY, ORPIL, SYDEY 2, and ALADIN III 
studies, comprising a total of 1160 people were selected 
(see Tables 1 and 2 for summaries of the studies). The study 
populations included individuals ranging in age from 18 to 
74 years with type 1 and 2 DM. Mean body mass indices 
ranged from 27.7 to 30.9. On average, initial glycosylated 
hemoglobin was ,12%. The average duration of DM 
ranged from 10.4 to 15.1 years, while that of DSPN ranged 
from 2.8 to 5 years. The studies took place in inpatient and 
outpatient treatment centers throughout Germany,   Russia, 
and Israel. The trials relied on mono- and multicenter 
participation.20,34–37
The five studies evaluated the effectiveness of ALA on 
DSPN using three different types of drug administration. Two 
studies evaluated the role of parental ALA compared with 
placebo.20,37 The parenteral treatment was given to separate 
intervention groups in doses of 100 mg daily, 600 mg daily, 
and 1200 mg daily. A total of 14 treatments were given over 
3 weeks in both studies.20,37 Two of the studies examined 
the effects of oral ALA relative to control patients with 
DSPN.34,35 Oral treatment was given to individual groups 
at total daily doses of 600 mg, 1200 mg, and 1800 mg. 
Duration of treatment ranged from 3 to 5 weeks.34,35 One trial 
included a combination of parenteral and oral alpha lipoic 
acid given sequentially.36 Combination therapy included 
schedules of ALA 600 mg iv daily for 3 weeks prior to 
1800 mg orally daily for 6 months and 600 mg iv daily prior 
to oral placebo for 6 months versus iv placebo treatment 
followed by oral placebo treatment. The total study duration 
was 7 months.36
The trials included a variety of outcome measures including 
symptom scores, clinical signs, and electrophysiology. 
All 5 included trials used the subjective measure of Total 
Symptom Score (TSS) as the primary endpoint (Table 3). 
The TSS is the summation of the presence, severity, and 
duration of lancinating pain, burning pain, prickling, and 
numbness. Total scores can range from 0 to 14.64; a peak 
score suggests the continuous presence of severe discomfort 
in all four symptom domains. Beyond statistically significant 
changes in the measure, a clinically meaningful improvement 
in TSS was defined as a mean difference of at least 1.83 
points.34,38 Several secondary measures of patient experience 
were also reported, including the four individual components 
of the TSS, the Number-Severity-Change (NSC) metric, the 
Global Assessment of Efficacy (GAE), and the Hamburg 
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Table 1 Placebo-controlled trials studying the efficacy of parenteral and oral alpha lipoic acid in the treatment of symptoms, clinical 
signs, and electrophysiology of diabetic sensorimotor polyneuropathy
Trial N Trial 
duration
Route Treatment arms Subjective measures of 
improvement reaching 
statistical significance 
relative to placebo  
(P , 0.05)
Clinical measures 
of improvement 
reaching statistical 
significance relative 
to placebo (P , 0.05)
Electrophysiological 
measures of 
improvement 
reaching statistical 
significance relative 
to placebo  
(P , 0.05)
TSS NSC GAe HPAL NIS NDS
ALADIN 326 3 weeks iv *ALA 100 mg daily 
*ALA 600 mg daily 
*ALA 1200 mg daily
x 
 

NA x 
 
x
x 
 

NA x 
x 

NA
SYDNeY 120 3 weeksa iv *ALA 600 mg daily  b  NA  NA  distal latency of 
sural nerve
ORPIL 24 3 weeks po *ALA 600 mg three 
times daily
 NA NA x NA  NA
SYDNeY 2 181 5 weeksa po *ALA 600 mg daily 
*ALA 1200 mg daily 
*ALA 1800 mg daily
 
 

 
 
c
 
 

NA x 
 
x
NA Results not reported
ALADIN III 509 3 weeks/ 
6 months
iv/po *ALA 600 mg daily/
placebo 
*ALA 600 mg daily/ 
600 mg three times 
daily
x/x 
 
x/x
NA NA NA /x 
 
/x
NA NA
Notes: N, number of participants initially enrolled; , significance was achieved; x, significance was not achieved; afollowing a 1-week placebo run-in phase; bstatistical 
significance was achieved for positive and negative sensory, but not motor and autonomic, symptoms; call metrics were significant except NSC number.
Abbreviations: TSS, Total Symptom Score; NSC, Number, Severity, Change; GAE, Global Assessment of Efficacy; HPAL, Hamburg Pain Adjective List; NIS, Neuropathy 
Impairment Score; NDS, Neuropathy Disability Score; iv, intravenous; po, oral; ALA, alpha lipoic acid; NA, not applicable.
In addition to measures of subjective improvement, 
studies also gauged the effect of ALA on measurable 
clinical signs. Two secondary measures comprised the 
Neuropathy Impairment Score (NIS) and the NIS in the 
lower limbs (NIS-LL). Endpoints also included the Neu-
ropathy Disability Scale (NDS), a quantified neurological 
examination derived from cranial nerve, sensory, motor, and 
reflex integrity.39 Electrophysiological measures variably 
included amplitude, velocity, and latency of the tibial and 
peroneal nerves in addition to the amplitude and latency of 
the sural nerve.
ALA efficacy: parenteral administration
In the Alpha-Lipoic Acid in Diabetic Neuropathy (ALADIN) 
Trial, (level of evidence 1b),32 328 patients with DM 2 
were recruited. Three hundred and twenty-six participants 
were randomized to one of four groups in a multicenter, 
double-blind, placebo controlled study. Eighty-two patients 
were given a placebo. Members of treatment groups received 
ALA at doses of 100 mg per day (n = 81), 600 mg per 
day (n = 77), or 1200 mg per day (n = 86) by iv. The drug 
was administered on 14 days over the course of 3 weeks. 
A significant decrease in TSS was noted in the intervention 
group relative to placebo by day 5; the effect was maintained 
until treatment end. There was no significant difference 
between the mean changes in TSS scores for the 100 mg 
per day treatment group and the placebo group. In addition 
to significant improvements from baseline TSS (5 points, 
P , 0.001 in the 600 mg group, 4.5 points, P = 0.003 in the 
1200 mg group), there were significant improvements in the 
components of burning, paresthesias, and numbness in the 
600 mg and 1200 mg groups (P < 0.05). The percentage of 
patients who experienced a clinically meaningful response 
reached significance in the 600 mg per day group relative 
to placebo (P = 0.002). The HPAL showed commensurate 
reductions in pain with both treatment groups compared with 
placebo (P , 0.001). Physicians rated global efficacy of ALA 
as very good or good in a significantly greater proportion of 
patients in the 600 mg per day treatment group relative to 
placebo (P = 0.001). A dose of 1200 mg per day resulted in Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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significant change in the NDS (P = 0.03). Of the 326 initially 
enrolled, 260 participants completed the trial. Adverse events 
were reported in all groups but only reached significance in 
the 1200 mg per day arm (P , 0.05), with side effects includ-
ing headache, nausea, and vomiting.37
The Symptomatic Diabetic Neuropathy (SYDNEY) 
Trial (level of evidence 1b)32 was an inpatient, single-center, 
randomized, double-masked placebo-controlled trial 
including a total of 120 patients with type 1 and 2 DM. 
Sixty participants were randomized to receive 600 mg of 
ALA and 60 were randomized to receive a placebo. There 
was a 1-week placebo run-in phase for both groups. The 
trial was conducted over the next 3 weeks, during which 
time 14 doses of ALA or placebo were given parenterally. 
Similar to the results of the ALADIN trial, a significant 
treatment effect was first appreciated in the experimental 
group relative to the placebo group by day 4; there was 
subsequent steady improvement thereafter. On the last day, 
the TSS of patients in the treatment group had improved 
by a mean of 5.72 points (P , 0.001). Further, there was 
significant improvement in all components (pain, burning, 
paresthesias, and numbness) measured by the TSS. Confirm-
ing the beneficial relationship between ALA and subjective 
relief, the SYDNEY Trial showed significant amelioration 
in the mean change of positive and negative sensory symp-
toms by the NSC metric (P , 0.05), although there was 
no significant improvement in perceptions of weakness. 
Patients rated the global efficacy of ALA as very good or 
good in a significantly greater proportion of participants 
in the 600 mg per day treatment group relative to placebo   
(P , 0.01). Significant improvement in NIS scores (2.7 
points, P , 0.001) was also observed. The distal latency of 
the sural nerve was significantly shorter in the ALA group 
than in the placebo group (P = 0.017); however, no other 
significant effects on nerve conduction were identified. Of 
120 participants, seven given placebo and one taking ALA 
Table 2 Placebo-controlled trials studying the safety of parenteral and oral alpha lipoic acid in the treatment of symptomatic diabetic 
sensorimotor polyneuropathy
Trial N Trial 
duration
Route Study groups Percentages 
of participants 
reporting 
adverse effects
Adverse effects 
reaching statistical 
significance relative 
to placebo (P , 0.05)
Types of adverse effects 
reported
ALADIN 326 3 weeks iv *Placebo 
*ALA 100 mg daily 
*ALA 600 mg daily 
*ALA 1200 mg daily
20.7% 
13.6% 
18.2% 
32.6%
 
x 
x 

 
Headache, nausea, vomiting
SYDNeY 120 3 weeks iv *Placebo 
*ALA 600 mg daily
5.8%a 
0.83%a
Not reported Not specifiedc
ORPIL 24 3 weeks po *Placebo 
*ALA 600 mg three 
times daily
4.17%a 
None reported
Not reported Myocardial infarctiond
SYDNeY 2 181 5 weeks po *Placebo 
*ALA 600 mg daily 
*ALA 1200 mg daily 
*ALA 1800 mg daily
21% 
27% 
43% 
54%
 
x 
 

 
Nausea, vomiting, vertigo
ALADIN III 509 3 weeks/ 
6 months
iv/po *Placebo/placebo 
*ALA 600 mg daily/
placebo 
*ALA 600 mg daily/ 
600 mg three times daily
44.6%b 
37.9%b 
 
46.1%b
 
x 
 
x
 
Not specified
Notes: N, number of participants initially enrolled; , significance was achieved; x, significance was not achieved; avalues calculated from data provided in paper; brates 
reflect adverse effects from oral phase; cnone of the adverse events were deemed related to the trial medication; dthe myocardial infarction was experienced by a member 
of the placebo group.
Abbreviations: iv, intravenous; po, oral; ALA, alpha lipoic acid.
Table 3 Total Symptom Score measure for sticking or lancinating 
pain, burning, prickling, and numbness
Symptom frequency Symptom intensity
Absent Slight Moderate Severe
Occasional 0 1 2 3
Often 0 1.33 2.33 3.33
Continuous 0 1.66 2.66 3.66Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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reported unspecified adverse effects. None of the side effects 
were considered causally related to the experimental agent.   
One hundred eighteen participants completed the trial.20
ALA efficacy: oral administration
Twenty-four patients with DM 2 participated in the Oral 
Pilot (ORPIL) trial (level of evidence 1b),32 a single-
center randomized, double-blind placebo-controlled study. 
Twelve patients were assigned to the placebo group. Twelve 
patients were assigned to a treatment group, in which ALA 
600 mg was administered orally three times daily. The 
trial demonstrated that a 3-week course of oral ALA at a 
dose of 1800 mg a day translates into a significant reduc-
tion in the mean TSS for the feet (3.75 points, P = 0.021). 
After 3 weeks, those in the treatment group also reported 
a significant improvement in the burning component of the 
TSS (P = 0.012). HPAL scores decreased but not to a level 
of significance.   Relative to   placebo, there was significant 
improvement in the NDS for the treatment group (P = 0.025). 
A total of 22 participants completed the trial. There were 
no differences in the adverse events between groups, and no 
specific side effects were reported.35
The findings were supported by the SYDNEY 2 
trial (level of evidence 1b),32 a multicenter double-blind 
placebo-controlled study conducted over 5 weeks. In the 
study, 181 participants with DM 1 and 2 were randomized to 
receive a placebo (n = 43), ALA 600 mg per day (n = 45), ALA 
1200 mg per day (n = 47) or ALA 1800 mg per day (n = 46). 
Treatment was started after a 1-week placebo run-in phase. 
Significant improvements in TSS were noted by week 1 in the 
1800 mg group and by week 2 in the 600 and 1200 mg groups. 
The significant improvements in total TSS were maintained 
at treatment end with all active doses (P , 0.05). Consistent 
with the ORPIL trial, the agent most effectively alleviated 
symptoms of pain and burning. Significant improvements 
were seen in NSC scores for all ALA doses relative to placebo 
(P , 0.05 except NSC number in ALA 1800, P = 0.08). 
Members of all ALA groups rated treatment significantly 
more favorably than those in the placebo group (P < 0.05). 
Interestingly, significant improvement in the overall NIS was 
noted only at a dose of 1200 mg (P < 0.05), while sensory 
function in the lower limbs (NIS-LL) improved significantly 
with ALA 600 mg per day over 5 weeks (P , 0.05). The 
results of nerve conduction studies were not reported. Of the 
initial 181 participants, 166 completed the trial. Fifteen left 
the study, mostly due to adverse effects including nausea, 
vomiting, and vertigo. Overall, side effects were reported by 
27% of the 600 mg group (P = 0.53), 43% of the 1200 mg 
group (P = 0.03), and 54% of those in the 1800 mg group 
(P , 0.001 relative to placebo).34
ALA efficacy: sequential parenteral  
and oral administration
Of the 509 participants initially enrolled, 383 completed 
the multicenter ALADIN III trial (level of evidence 2b).32 
Conducted over a total of 7 months, DM 2 patients were 
randomized to one of three groups; the first group received 
placebo in a 3-week iv phase and the subsequent 6-month oral 
phase (n = 168). The second group received ALA 600 mg iv 
daily for 3 weeks prior to oral placebo for 6 months (n = 174). 
The third group received ALA 600 mg iv daily for 3 weeks 
followed by ALA 600 mg three times daily for 6 months 
(n = 167). In contrast to the ALADIN and SYDNEY results, 
treatment with ALA 600 mg iv daily in the ALADIN III trial 
was not associated with significant changes in mean TSS-feet 
when compared with placebo at 3 weeks. After an additional 
6 months of 1800 mg per day oral therapy, the area under the 
curve was smaller in the active groups. However, there was no 
significant difference in symptoms as rated by the TSS after 
7 months between any of the active or control groups. The 
ALADIN III trial demonstrated improvement in NIS after the 
iv phase of treatment with ALA 600 mg per day over 3 weeks. 
However, there was no significant difference in NIS after an 
additional 6 months of oral treatment at a dose of 600 mg 
three times daily relative to placebo. The rates of side effects 
were not significantly different between groups.36
Summary of data and discussion
The current appraisal includes data derived from a total of 
1160 participants enrolled in the ALADIN, SYDNEY, ORPIL, 
SYDNEY 2, and ALADIN III studies. Two trials comprising 
446 patients in total explored the efficacy and safety of short-
term parenteral ALA treatment versus placebo. Compared 
with placebo, iv ALA was associated with significant, 
clinically meaningful improvements in sensory symptoms 
and neuropathic deficits. Doses of 600 mg daily and 1200 mg 
daily offered equivalent benefits, but the higher dose was 
associated with significantly more side effects than placebo. 
The results were confirmed in a meta-analysis pooling data 
from a total of 1258 participants in the ALADIN, ALADIN 
III, SYDNEY, and NATHAN II trials.40 While the validity 
of the research has been challenged,32,38 the work indicated 
that ALA 600 mg iv daily for 3 weeks translates into a clear 
therapeutic benefit without significant side effects.40
Two trials consisting of 205 patients total evaluated 
the effectiveness and tolerability of short-term oral ALA Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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treatment with placebo. Relative to placebo, oral ALA 
alleviated symptoms and impairments to a significant and 
clinically meaningful degree at total daily doses of 600 mg, 
1200 mg, and 1800 mg. However, there was evidence of dose-
related toxicity, with adverse event rates reaching significance 
at a dose of 1200 mg and climbing at a dose of 1800 mg daily 
after 5 weeks. The combination of parenteral (600 mg daily 
for 3 weeks) and oral therapy (600 mg three times daily for 
6 months) administered over a total of 7 months failed to 
translate into significant improvements.
Studies exploring the efficacy of parenteral and oral 
ALA on the symptoms, signs, and electrophysiological 
parameters of DSPN date back to at least 1959.41 Validity 
of data from initial trials is constrained by small sample 
size, lack of blinding, absence of placebo control, and 
potentially inadequate treatment doses.38 While the quality of 
investigations has improved over time, even the most recent 
randomized double-blind placebo-controlled trials have some 
methodological limitations.38,42 Further, none provides true 
Class I evidence.
Although investigators of the reviewed trials may have 
calculated the number participants necessary to detect 
meaningful change in study endpoints, ultimate sample 
size was sometimes inadequate due to participant attrition; 
drop-out rate reached 25% in one of the studies included 
in the present analysis.36 Further, the incorporation of as 
many as 71 treatment sites in multicenter designs likely 
introduced variability in scoring that affected outcomes.36 
Patients with DM 1 and DM 2 were included in the studies 
reviewed here. While DSPN represents an important clinical 
problem in both populations, the pathophysiology and 
response to treatment could differ. Similarly, the magnitude 
of therapeutic effect could be contingent on baseline status, 
and initial TSS varied widely across studies. While patients 
with a baseline TSS of at least 2 were included in one study,37 
other trials required TSS be at least 7.5.20,34 Concurrent 
administration of certain diabetic therapies and antioxidants 
with ALA could also have influenced results. In three of 
the studies reviewed, use of diet, oral antidiabetics, and/or 
insulin constituted a criterion for inclusion.35–37 Although 
details of the therapies were not outlined, the authors noted 
the continuation of usual diabetic treatment throughout the 
study period in one instance.20 Importantly, not all of the 
trials specifically excluded patients who were using, or had 
recently used, other antioxidants.20
Whereas the randomized controlled trials reviewed dem-
onstrate significant improvement in symptoms and signs of 
neuropathy, there is little evidence that ALA has a meaningful 
effect on nerve conduction. One potential explanation is that 
ALA preferentially treats small fiber neuropathy, which is 
not measurable by electrodiagnostic studies. Alternatively, 
objective improvements in some clinical signs and nerve 
conduction could take years to manifest. Preliminary support 
for this notion is provided by two long-term studies. Despite 
methodological flaws, the ALADIN II trial demonstrated that 
treatment with ALA at doses of 600 mg and 1200 mg given 
parenterally for 5 days and then orally for 2 years led to 
significant improvements in nerve conduction.30 The interna-
tional NATHAN I trial showed that neuropathy progressed in 
placebo conditions but improved with oral ALA 600  mg daily 
over 4 years.43 Future trials evaluating long-term administra-
tion of ALA could better define the patterns of effectiveness 
and tolerability of the agent over years.
All of the reviewed studies suggest ALA is safe at a 
once daily dose of 600 mg in both iv and oral forms. The 
investigations also demonstrate significant toxicity emerges 
at a dose of 1200 mg once daily with both routes of admin-
istration after 3–5 weeks of treatment.34,37 Interestingly, 
ALA at a total daily dose of 1800 mg was well tolerated 
when administered in three divided doses for as long as   
6 months35,36 but not as a single daily dose over just 5 weeks.34 
The trend raises the possibility that higher amounts of ALA 
could be well-tolerated if given in smaller divided doses. 
Of note, the drug formulations varied across the studies and 
could have influenced side effect rates and symptom relief 
in meaningful ways.
The current body of evidence suggests that both paren-
teral and oral forms of ALA can translate into statistically 
significant symptom relief within 1 week, with steady 
and continuous improvement thereafter.20,34,37 However, it 
is uncertain if the trajectory of improvement continues, 
  plateaus, or declines with prolonged treatment and following 
discontinuation of the agent. Some data indicate the benefits 
of ALA are not   sustained following therapy completion. One 
study showed that after the discontinuation of ALA 600 mg 
daily for a mean of 5 years, about 73% of patients developed 
  neuropathic symptoms within 2 weeks in the absence of 
gabapentin therapy.44 Authors maintain that transitioning 
from ALA to gabapentin and other conventional medications 
resulted in increased side effects, more outpatient visits, 
and heightened daily cost of therapy.44 While the return of 
symptoms could represent the natural course of disease, it 
is unclear if transient use of ALA could ultimately worsen 
symptoms.
In the absence of symptoms, patients with DSPN do not 
necessarily seek evaluation. As experimental models suggest Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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it has protective properties, starting ALA treatment at the 
time of DM diagnosis might improve its long-term benefits. 
Early initiation might be especially important because the 
ability to endogenously synthesize ALA declines with age 
in DM.30 In addition to optimal timing and duration of ALA 
therapy, future studies should explore the use of ALA in 
combination with other antioxidants given the multifaceted 
nature of oxidative stress in DSPN.
While there is some evidence that other antioxidants, 
such as vitamin E, can significantly ameliorate neuropathic 
symptoms  and  nerve  conduction  in  patients  with 
DM 2,45,46 larger scale trials generally fail to show 
significant improvements in hyperglycemia and diabetic 
complications.47,48 ALA could represent a superior treatment 
because it has unique properties as an antioxidant and insulin 
mimetic.14,22,30 Unlike other antioxidants, ALA is amphiphilic, 
allowing action in aqueous and lipid media.30 Thus, the 
positive effects of ALA on DSPN could reflect enhancement 
of its known role as a cofactor in mitochondrial reactions, 
but also in other systemic processes. Through downstream 
scavenging by DHLA and antioxidant recycling, ALA 
could initiate a cascade of events that continues to provide 
benefits long after its metabolism.14,22,30 Beyond its role as 
an antioxidant, ALA could also help mitigate complications 
of DM by improving insulin sensitivity and glucose 
disposal.14,22,30 Future studies should investigate optimal 
combinations of antidiabetic therapies and ALA.
Conclusion
Treatment with ALA 600 mg iv daily for 3 weeks represents 
a well-tolerated and effective therapy for DSPN. Similarly, 
an oral dose of 600 mg daily administered for up to 5 weeks 
could offer benefits in symptoms and signs of DSPN without 
  significant side effects. Whereas a single study using sequential 
parenteral and oral therapy failed to show a significant effect, 
the preponderance of evidence supports the use of ALA in 
treating the symptoms and signs of DSPN. Further random-
ized, double-blind, placebo-  controlled trials of larger scale and 
longer duration are necessary to strengthen existing data and 
provide greater insight into the long-term efficacy of ALA.
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